You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLosartan
Accession NumberDB00678  (APRD00052)
TypeSmall Molecule
GroupsApproved
DescriptionLosartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. Losartan and its longer acting metabolite, E-3174, lower blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); they compete with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Losartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of systolic dysfunction, myocardial infarction, coronary artery disease, and heart failure.
Structure
Thumb
Synonyms
(2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
2-N-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
DuP 89
Losartan
External Identifiers
  • MK594
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act LosartanTablet25 mgOralActavis Pharma Company2012-01-25Not applicableCanada
Act LosartanTablet50 mgOralActavis Pharma Company2012-01-25Not applicableCanada
Act LosartanTablet100 mgOralActavis Pharma Company2012-01-25Not applicableCanada
Ag-losartanTablet50 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-losartanTablet100 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-losartanTablet25 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Auro-losartanTablet25.0 mgOralAuro Pharma Inc2013-03-26Not applicableCanada
Auro-losartanTablet50.0 mgOralAuro Pharma Inc2013-03-26Not applicableCanada
Auro-losartanTablet100.0 mgOralAuro Pharma Inc2013-03-26Not applicableCanada
Bio-losartanTablet50 mgOralBiomed Pharma2016-05-09Not applicableCanada
Bio-losartanTablet100 mgOralBiomed Pharma2016-06-08Not applicableCanada
Bio-losartanTablet25 mgOralBiomed Pharma2016-05-09Not applicableCanada
CozaarTablet, film coated100 mg/1OralREMEDYREPACK INC.2011-04-222016-10-13Us
CozaarTablet, film coated25 mg/1OralMerck Sharp & Dohme Corp.1995-04-14Not applicableUs
CozaarTablet, film coated50 mg/1Oralbryant ranch prepack1995-04-14Not applicableUs
CozaarTablet, film coated25 mg/1OralPhysicians Total Care, Inc.2004-06-02Not applicableUs
CozaarTablet100 mgOralMerck Canada Inc1998-01-16Not applicableCanada
CozaarTablet, film coated25 mg/1OralREMEDYREPACK INC.2011-05-192016-10-13Us
CozaarTablet, film coated50 mg/1OralMerck Sharp & Dohme Corp.1995-04-14Not applicableUs
CozaarTablet, film coated100 mg/1Oralbryant ranch prepack1995-04-14Not applicableUs
CozaarTablet, film coated25 mg/1OralCardinal Health1995-04-14Not applicableUs
CozaarTablet, film coated100 mg/1OralPhysicians Total Care, Inc.2003-08-06Not applicableUs
CozaarTablet, film coated100 mg/1OralMerck Sharp & Dohme Corp.1995-04-14Not applicableUs
CozaarTablet25 mgOralMerck Canada Inc1995-12-31Not applicableCanada
CozaarTablet, film coated50 mg/1OralCardinal Health1995-04-14Not applicableUs
CozaarTablet25 mg/1OralREMEDYREPACK INC.2011-04-072016-10-13Us
CozaarTablet, film coated50 mg/1OralPhysicians Total Care, Inc.1996-04-01Not applicableUs
CozaarTablet50 mgOralMerck Canada Inc1995-12-31Not applicableCanada
CozaarTablet, film coated100 mg/1OralPd Rx Pharmaceuticals, Inc.1995-04-14Not applicableUs
Ipg-losartanTablet50 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-losartanTablet25 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-losartanTablet100 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-losartanTablet25 mgOralJamp Pharma Corporation2013-06-11Not applicableCanada
Jamp-losartanTablet50 mgOralJamp Pharma Corporation2013-06-11Not applicableCanada
Jamp-losartanTablet100 mgOralJamp Pharma Corporation2013-06-11Not applicableCanada
LosartanTablet25 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
LosartanTablet50 mgOralSivem Pharmaceuticals Ulc2012-07-05Not applicableCanada
LosartanTablet50 mgOralPro Doc Limitee2012-11-22Not applicableCanada
LosartanTablet25 mgOralFrosst A Division Of Merck Canada IncNot applicableNot applicableCanada
LosartanTablet25 mgOralSanis Health Inc2012-07-20Not applicableCanada
LosartanTablet50 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
LosartanTablet100 mgOralSivem Pharmaceuticals Ulc2012-07-05Not applicableCanada
LosartanTablet25 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
LosartanTablet100 mgOralPro Doc Limitee2012-11-22Not applicableCanada
LosartanTablet50 mgOralFrosst A Division Of Merck Canada IncNot applicableNot applicableCanada
LosartanTablet50 mgOralSanis Health Inc2012-07-20Not applicableCanada
LosartanTablet100 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
LosartanTablet50 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
LosartanTablet100 mgOralFrosst A Division Of Merck Canada IncNot applicableNot applicableCanada
LosartanTablet100 mgOralSanis Health Inc2012-07-20Not applicableCanada
LosartanTablet25 mgOralPro Doc Limitee2012-11-22Not applicableCanada
LosartanTablet100 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
LosartanTablet25 mgOralSivem Pharmaceuticals Ulc2012-07-05Not applicableCanada
Losartan PotassiumTablet50 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
Losartan PotassiumTablet, film coated50 mg/1OralSandoz Inc.1995-04-14Not applicableUs
Losartan PotassiumTablet50 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
Losartan PotassiumTablet, film coated100 mg/1OralSandoz Inc.1995-04-14Not applicableUs
Losartan PotassiumTablet25 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
Losartan PotassiumTablet100 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
Losartan PotassiumTablet25 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
Losartan PotassiumTablet100 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
Losartan PotassiumTablet, film coated25 mg/1OralSandoz Inc.1995-04-14Not applicableUs
Mar-losartanTablet25 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-losartanTablet50 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-losartanTablet100 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mint-losartanTablet100.0 mgOralMint Pharmaceuticals Inc2014-01-16Not applicableCanada
Mint-losartanTablet25.0 mgOralMint Pharmaceuticals Inc2014-01-16Not applicableCanada
Mint-losartanTablet50.0 mgOralMint Pharmaceuticals Inc2014-01-16Not applicableCanada
Mylan-losartanTablet25 mgOralMylan Pharmaceuticals Ulc2012-01-25Not applicableCanada
Mylan-losartanTablet50 mgOralMylan Pharmaceuticals Ulc2012-01-25Not applicableCanada
Mylan-losartanTablet100 mgOralMylan Pharmaceuticals Ulc2012-01-25Not applicableCanada
PMS-losartanTablet100 mgOralPharmascience Inc2012-01-25Not applicableCanada
PMS-losartanTablet25 mgOralPharmascience Inc2012-01-25Not applicableCanada
PMS-losartanTablet50 mgOralPharmascience Inc2012-01-25Not applicableCanada
Priva-losartanTablet50 mgOralPharmapar Inc2016-05-09Not applicableCanada
Priva-losartanTablet100 mgOralPharmapar Inc2016-05-25Not applicableCanada
Priva-losartanTablet25 mgOralPharmapar Inc2016-05-25Not applicableCanada
Ran-losartanTablet50 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-losartanTablet100 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Ran-losartanTablet25 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-06-11Not applicableCanada
Sandoz LosartanTablet25 mgOralSandoz Canada Incorporated2012-01-25Not applicableCanada
Sandoz LosartanTablet50 mgOralSandoz Canada Incorporated2012-01-25Not applicableCanada
Sandoz LosartanTablet100 mgOralSandoz Canada Incorporated2012-01-25Not applicableCanada
Septa-losartanTablet25 mgOralSepta Pharmaceuticals Inc2014-07-03Not applicableCanada
Septa-losartanTablet50 mgOralSepta Pharmaceuticals Inc2014-07-03Not applicableCanada
Septa-losartanTablet100 mgOralSepta Pharmaceuticals Inc2014-07-03Not applicableCanada
Teva-losartanTablet50 mgOralTeva Canada Limited2012-01-25Not applicableCanada
Teva-losartanTablet25 mgOralTeva Canada Limited2012-02-28Not applicableCanada
Teva-losartanTablet100 mgOralTeva Canada Limited2012-01-25Not applicableCanada
Van-losartanTablet100 mgOralVanc Pharmaceuticals Inc2015-06-08Not applicableCanada
Van-losartanTablet25 mgOralVanc Pharmaceuticals Inc2015-06-08Not applicableCanada
Van-losartanTablet50 mgOralVanc Pharmaceuticals Inc2015-06-08Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-losartanTablet50 mgOralApotex Inc2012-01-25Not applicableCanada
Apo-losartanTablet100 mgOralApotex Inc2012-01-25Not applicableCanada
Apo-losartanTablet25 mgOralApotex Inc2012-04-13Not applicableCanada
LosartanTablet, film coated50 mg/1OralVirtus Pharmaceuticals2015-07-14Not applicableUs
LosartanTablet, film coated25 mg/1OralMethod Pharmaceuticals, Llc2015-07-14Not applicableUs
LosartanTablet, film coated100 mg/1OralVirtus Pharmaceuticals2015-07-14Not applicableUs
LosartanTablet, film coated50 mg/1OralMethod Pharmaceuticals, Llc2016-09-20Not applicableUs
LosartanTablet, film coated25 mg/1OralVirtus Pharmaceuticals2015-07-14Not applicableUs
LosartanTablet, film coated100 mg/1OralMethod Pharmaceuticals, Llc2016-09-20Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralPd Rx Pharmaceuticals, Inc.2010-10-06Not applicableUs
Losartan PotassiumTablet50 mg/1OralMajor Pharmaceuticals2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralProficient Rx LP2010-04-06Not applicableUs
Losartan PotassiumTablet25 mg/1OralClinical Solutions Wholesale2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralAurobindo Pharma Limited2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralCitron Pharma LLC2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralSolco Healthcare US, LLC2014-07-30Not applicableUs
Losartan PotassiumTablet25 mg/1OralLegacy Pharmaceutical Packaging, Llc2010-10-06Not applicableUs
Losartan PotassiumTablet100 mg/1OralA S Medication Solutions2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralQualitest Pharmaceuticals2012-01-042016-11-10Us
Losartan PotassiumTablet100 mg/1OralUnichem Pharmaceuticals (USA), Inc.2016-01-01Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralGolden State Medical Supply, Inc.2011-02-22Not applicableUs
Losartan PotassiumTablet25 mg/1OralWest Ward Pharmaceuticals Corp.2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-11-12Not applicableUs
Losartan PotassiumTablet50 mg/1OralREMEDYREPACK INC.2013-01-16Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralReady Meds2012-01-04Not applicableUs
Losartan PotassiumTablet25 mg/1OralA S Medication Solutions2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralREMEDYREPACK INC.2016-10-07Not applicableUs
Losartan PotassiumTablet25 mg/1OralCarilion Materials Management2010-10-06Not applicableUs
Losartan PotassiumTablet50 mg/1OralPreferred Pharmaceuticals, Inc.2013-06-06Not applicableUs
Losartan PotassiumTablet100 mg/1OralLupin Pharmaceuticals, Inc.2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralTeva Pharmaceuticals USA Inc2010-04-06Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralRising Pharmaceuticals, Inc2014-07-30Not applicableUs
Losartan PotassiumTablet50 mg/1OralAv Pak2014-03-27Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralPhysicians Total Care, Inc.2010-04-13Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-06Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralMacleods Pharmaceuticals Limited2012-05-10Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralApotex Corp2010-10-03Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralPd Rx Pharmaceuticals, Inc.2010-10-06Not applicableUs
Losartan PotassiumTablet50 mg/1OralTorrent Pharmaceuticals Limited2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2010-10-03Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralDispensing Solutions, Inc.2010-12-28Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralREMEDYREPACK INC.2016-05-04Not applicableUs
Losartan PotassiumTablet25 mg/1OralREMEDYREPACK INC.2011-07-152016-10-28Us
Losartan PotassiumTablet, film coated50 mg/1OralLegacy Pharmaceutical Packaging, Llc2010-04-06Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralCamber Pharmaceuticals, Inc.2015-08-19Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralVirtus Pharmaceuticals LLC2014-03-25Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralWatson Laboratories, Inc.2011-02-22Not applicableUs
Losartan PotassiumTablet100 mg/1OralUnit Dose Services2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralClinical Solutions Wholesale2010-04-06Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralSandoz Inc2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralMylan Pharmaceuticals Inc.2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralCadila Healthcare Limited2010-10-04Not applicableUs
Losartan PotassiumTablet100 mg/1OralA S Medication Solutions2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralProficient Rx LP2015-08-19Not applicableUs
Losartan PotassiumTablet100 mg/1OralLupin Pharmaceuticals, Inc.2015-12-022016-11-29Us
Losartan PotassiumTablet, film coated100 mg/1OralPreferred Pharmaceuticals Inc.2016-10-17Not applicableUs
Losartan PotassiumTablet100 mg/1OralPreferred Pharmaceuticals, Inc.2015-05-07Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralAvera Mc Kennan Hospital2015-03-09Not applicableUs
Losartan PotassiumTablet25 mg/1OralMajor Pharmaceuticals2010-10-06Not applicableUs
Losartan PotassiumTablet100 mg/1OralREMEDYREPACK INC.2015-02-06Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralMed Vantx, Inc.2010-10-03Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralSolco Healthcare US, LLC2014-07-30Not applicableUs
Losartan PotassiumTablet50 mg/1OralLegacy Pharmaceutical Packaging, Llc2010-10-06Not applicableUs
Losartan PotassiumTablet25 mg/1OralLegacy Pharmaceutical Packaging2010-10-06Not applicableUs
Losartan PotassiumTablet25 mg/1OralPreferred Pharmaceuticals Inc.2016-11-02Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralQualitest Pharmaceuticals2012-01-042016-11-10Us
Losartan PotassiumTablet100 mg/1OralREMEDYREPACK INC.2013-05-14Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralGolden State Medical Supply, Inc.2011-02-22Not applicableUs
Losartan PotassiumTablet50 mg/1OralWest Ward Pharmaceuticals Corp.2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-11-12Not applicableUs
Losartan PotassiumTablet25 mg/1OralREMEDYREPACK INC.2014-04-09Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralReady Meds2012-01-04Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralA S Medication Solutions2014-07-30Not applicableUs
Losartan PotassiumTablet100 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralCarilion Materials Management2010-04-06Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralA S Medication Solutions2010-04-06Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralPreferred Pharmaceuticals, Inc.2011-03-21Not applicableUs
Losartan PotassiumTablet50 mg/1OralLegacy Pharmaceutical Packaging, Llc2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralTeva Pharmaceuticals USA Inc2010-04-06Not applicableUs
Losartan PotassiumTablet100 mg/1OralSTAT Rx USA LLC2010-10-06Not applicableUs
Losartan PotassiumTablet100 mg/1OralAv Pak2014-03-27Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralPhysicians Total Care, Inc.2010-04-13Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralVirtus Pharmaceuticals LLC2014-03-25Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-06Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralMacleods Pharmaceuticals Limited2012-06-01Not applicableUs
Losartan PotassiumTablet100 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Losartan PotassiumTablet50 mg/1OralSt Marys Medical Park Pharmacy2013-07-11Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralMicro Labs Limited2012-12-06Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2010-10-03Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralREMEDYREPACK INC.2016-06-15Not applicableUs
Losartan PotassiumTablet25 mg/1OralREMEDYREPACK INC.2011-12-07Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralPreferred Pharmaceuticals, Inc2016-08-15Not applicableUs
Losartan PotassiumTablet100 mg/1OralLegacy Pharmaceutical Packaging2010-10-06Not applicableUs
Losartan PotassiumTablet100 mg/1OralDIRECT RX2014-01-01Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralAvera Mc Kennan Hospital2015-03-01Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralWatson Laboratories, Inc.2011-02-22Not applicableUs
Losartan PotassiumTablet25 mg/1OralUnichem Pharmaceuticals (USA), Inc.2016-01-01Not applicableUs
Losartan PotassiumTablet50 mg/1OralREMEDYREPACK INC.2013-02-26Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralSandoz Inc2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralMylan Pharmaceuticals Inc.2010-10-06Not applicableUs
Losartan PotassiumTablet100 mg/1OralClinical Solutions Wholesale2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralAurobindo Pharma Limited2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralCitron Pharma LLC2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralPd Rx Pharmaceuticals, Inc.2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralProficient Rx LP2015-08-19Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralApotex Corp2010-10-03Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralKAISER FOUNDATION HOSPITALS2016-03-16Not applicableUs
Losartan PotassiumTablet25 mg/1OralTorrent Pharmaceuticals Limited2010-10-06Not applicableUs
Losartan PotassiumTablet50 mg/1OralDIRECT RX2015-01-01Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralMed Vantx, Inc.2010-12-28Not applicableUs
Losartan PotassiumTablet100 mg/1OralLegacy Pharmaceutical Packaging, Llc2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralLegacy Pharmaceutical Packaging, Llc2010-04-06Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralCamber Pharmaceuticals, Inc.2015-08-19Not applicableUs
Losartan PotassiumTablet50 mg/1OralLife Line Home Care Services, Inc.2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralQualitest Pharmaceuticals2012-01-042016-11-10Us
Losartan PotassiumTablet25 mg/1OralUnit Dose Services2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralPhysicians Total Care, Inc.2010-04-27Not applicableUs
Losartan PotassiumTablet100 mg/1OralWest Ward Pharmaceuticals Corp.2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralEndo Pharmaceuticals Inc. DBA Endo Generic Products2010-11-12Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralCadila Healthcare Limited2010-10-04Not applicableUs
Losartan PotassiumTablet50 mg/1OralA S Medication Solutions2010-10-06Not applicableUs
Losartan PotassiumTablet50 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-10-06Not applicableUs
Losartan PotassiumTablet25 mg/1OralLupin Pharmaceuticals, Inc.2015-12-022016-11-29Us
Losartan PotassiumTablet, film coated100 mg/1OralPreferred Pharmaceuticals, Inc.2013-01-25Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralTeva Pharmaceuticals USA Inc2010-04-06Not applicableUs
Losartan PotassiumTablet50 mg/1OralREMEDYREPACK INC.2013-03-082016-10-29Us
Losartan PotassiumTablet, film coated50 mg/1OralPreferred Pharmaceuticals Inc.2016-09-08Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralLegacy Pharmaceutical Packaging, Llc2010-04-06Not applicableUs
Losartan PotassiumTablet25 mg/1OralLupin Pharmaceuticals, Inc.2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralVirtus Pharmaceuticals LLC2014-03-25Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralRising Pharmaceuticals, Inc2011-06-01Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralMacleods Pharmaceuticals Limited2012-06-01Not applicableUs
Losartan PotassiumTablet50 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Losartan PotassiumTablet100 mg/1OralSt Marys Medical Park Pharmacy2013-07-11Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralMicro Labs Limited2012-12-06Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2010-10-03Not applicableUs
Losartan PotassiumTablet50 mg/1OralA S Medication Solutions2010-10-062016-10-26Us
Losartan PotassiumTablet, film coated50 mg/1OralREMEDYREPACK INC.2016-06-15Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralAurobindo Pharma Limited2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralCitron Pharma LLC2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralSolco Healthcare US, LLC2011-06-01Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralProficient Rx LP2015-08-19Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralUnit Dose Services2011-06-01Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralWatson Laboratories, Inc.2011-02-22Not applicableUs
Losartan PotassiumTablet50 mg/1OralUnichem Pharmaceuticals (USA), Inc.2016-01-01Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralREMEDYREPACK INC.2012-12-27Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralGolden State Medical Supply, Inc.2011-02-22Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralREMEDYREPACK INC.2015-09-17Not applicableUs
Losartan PotassiumTablet100 mg/1OralMajor Pharmaceuticals2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralProficient Rx LP2012-01-04Not applicableUs
Losartan PotassiumTablet50 mg/1OralClinical Solutions Wholesale2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralApotex Corp2010-10-03Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralKAISER FOUNDATION HOSPITALS2016-03-16Not applicableUs
Losartan PotassiumTablet100 mg/1OralTorrent Pharmaceuticals Limited2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1Oralbryant ranch prepack2010-10-03Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralDispensing Solutions, Inc.2010-12-28Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralMedsource Pharmaceuticals2010-04-06Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralPreferred Pharmaceuticals, Inc.2016-06-09Not applicableUs
Losartan PotassiumTablet50 mg/1OralLegacy Pharmaceutical Packaging2011-02-21Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralCamber Pharmaceuticals, Inc.2015-08-19Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralMc Kesson Contract Packaging2013-04-10Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-06Not applicableUs
Losartan PotassiumTablet50 mg/1OralUnit Dose Services2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralCardinal Health2011-08-12Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralSandoz Inc2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralMylan Pharmaceuticals Inc.2010-10-06Not applicableUs
Losartan PotassiumTablet25 mg/1OralDIRECT RX2015-12-03Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralCadila Healthcare Limited2010-10-04Not applicableUs
Losartan PotassiumTablet25 mg/1OralA S Medication Solutions2010-10-06Not applicableUs
Losartan PotassiumTablet25 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-10-06Not applicableUs
Losartan PotassiumTablet50 mg/1OralLupin Pharmaceuticals, Inc.2015-12-022016-11-29Us
Losartan PotassiumTablet, film coated50 mg/1OralPreferred Pharmaceuticals, Inc.2013-01-25Not applicableUs
Losartan PotassiumTablet, film coated25 mg/1OralKAISER FOUNDATION HOSPITALS2015-12-01Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralMc Kesson Packaging Services2010-10-04Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralA S Medication Solutions2014-07-30Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralREMEDYREPACK INC.2016-08-15Not applicableUs
Losartan PotassiumTablet25 mg/1OralAv Pak2014-03-27Not applicableUs
Losartan PotassiumTablet100 mg/1OralUnit Dose Services2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralLegacy Pharmaceutical Packaging2010-10-03Not applicableUs
Losartan PotassiumTablet50 mg/1OralLupin Pharmaceuticals, Inc.2010-10-06Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralAvera Mc Kennan Hospital2015-03-11Not applicableUs
Losartan PotassiumTablet, film coated50 mg/1OralRising Pharmaceuticals, Inc2014-07-30Not applicableUs
Losartan PotassiumTablet25 mg/1OralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
Losartan PotassiumTablet, film coated100 mg/1OralMicro Labs Limited2012-12-06Not applicableUs
Losartan Potassium Tablets, 100 mgTablet100 mg/1OralJubilant Cadista Pharmaceuticals Inc.2012-09-18Not applicableUs
Losartan Potassium Tablets, 25 mgTablet25 mg/1OralJubilant Cadista Pharmaceuticals Inc.2012-09-18Not applicableUs
Losartan Potassium Tablets, 50 mgTablet50 mg/1OralJubilant Cadista Pharmaceuticals Inc.2012-09-18Not applicableUs
Losartan PotatssiumTablet50 mg/1OralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Losatan PotassiumTablet, film coated25 mg/1OralAlembic Pharmaceuticals Inc.2016-05-23Not applicableUs
Losatan PotassiumTablet, film coated50 mg/1OralAlembic Pharmaceuticals Inc.2016-05-23Not applicableUs
Losatan PotassiumTablet, film coated100 mg/1OralAlembic Pharmaceuticals Inc.2016-05-23Not applicableUs
Losortan PotassiumTablet, film coated100 mg/1OralZydus Pharmaceuticals (USA) Inc.2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated50 mg/1OralREMEDYREPACK INC.2013-06-03Not applicableUs
Losortan PotassiumTablet, film coated50 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-10-14Not applicableUs
Losortan PotassiumTablet, film coated25 mg/1OralUnit Dose Services2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated50 mg/1OralPreferred Pharmaceuticals Inc2016-08-01Not applicableUs
Losortan PotassiumTablet, film coated25 mg/1OralRebel Distributors Corp2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated50 mg/1OralProficient Rx LP2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated100 mg/1OralCardinal Health2013-06-13Not applicableUs
Losortan PotassiumTablet, film coated100 mg/1OralPd Rx Pharmaceuticals, Inc.2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated50 mg/1Oralbryant ranch prepack2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated50 mg/1OralAidarex Pharmaceuticals LLC2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated25 mg/1OralAmerican Health Packaging2013-06-13Not applicableUs
Losortan PotassiumTablet, film coated25 mg/1OralZydus Pharmaceuticals (USA) Inc.2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated50 mg/1OralA S Medication Solutions2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated100 mg/1OralProficient Rx LP2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated100 mg/1Oralbryant ranch prepack2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated50 mg/1OralMedsource Pharmaceuticals2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated100 mg/1OralAidarex Pharmaceuticals LLC2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated25 mg/1OralREMEDYREPACK INC.2014-04-01Not applicableUs
Losortan PotassiumTablet, film coated50 mg/1OralCardinal Health2010-10-14Not applicableUs
Losortan PotassiumTablet, film coated25 mg/1OralMc Kesson Packaging Services a Business Unit of Mc Kesson Corp2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated50 mg/1OralRebel Distributors Corp2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated50 mg/1OralAmerican Health Packaging2013-06-13Not applicableUs
Losortan PotassiumTablet, film coated50 mg/1OralZydus Pharmaceuticals (USA) Inc.2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated25 mg/1OralAidarex Pharmaceuticals LLC2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated100 mg/1OralRebel Distributors Corp2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated25 mg/1OralCardinal Health2010-10-14Not applicableUs
Losortan PotassiumTablet, film coated50 mg/1OralMc Kesson Packaging Services a Business Unit of Mc Kesson Corp2010-10-04Not applicableUs
Losortan PotassiumTablet, film coated100 mg/1OralAmerican Health Packaging2013-06-13Not applicableUs
Losortan PotassiumTablet, film coated100 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-10-14Not applicableUs
Losortan PotassiumTablet, film coated50 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LortaanNot Available
Brand mixtures
NameLabellerIngredients
Act Losartan/hctActavis Pharma Company
Apo-losartan/hctzApotex Inc
Auro-losartan HctAuro Pharma Inc
HyzaarMerck Sharp & Dohme Corp.
Hyzaar 50/12.5mgMerck Canada Inc
Hyzaar DS 100/25 mgMerck Canada Inc
Jamp-losartan HctzJamp Pharma Corporation
Losartan HctSivem Pharmaceuticals Ulc
Losartan Potassium and HydrochlorothiazideTeva Pharmaceuticals USA Inc
Losartan-hctzPro Doc Limitee
Losartan/hctActavis Pharma Company
Losartan/hctzSanis Health Inc
Mint-losartan/hctzMint Pharmaceuticals Inc
Mint-losartan/hctz DSMint Pharmaceuticals Inc
Mylan-losartan HctzMylan Pharmaceuticals Ulc
PMS-losartan-hctzPharmascience Inc
Ratio-losartan HctzTeva Canada Limited
Sandoz Losartan HctSandoz Canada Incorporated
Sandoz Losartan Hct DSSandoz Canada Incorporated
Septa-losartan HctzSepta Pharmaceuticals Inc
Teva-losartan/hctzTeva Canada Limited
Van-losartan-hctzVanc Pharmaceuticals Inc
Salts
Name/CASStructureProperties
Losartan Potassium
Thumb
  • InChI Key: OXCMYAYHXIHQOA-UHFFFAOYSA-N
  • Monoisotopic Mass: 460.118068924
  • Average Mass: 461.001
DBSALT000112
Categories
UNIIJMS50MPO89
CAS number114798-26-4
WeightAverage: 422.911
Monoisotopic: 422.162187095
Chemical FormulaC22H23ClN6O
InChI KeyPSIFNNKUMBGKDQ-UHFFFAOYSA-N
InChI
InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
IUPAC Name
[2-butyl-4-chloro-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazol-5-yl]methanol
SMILES
CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Pharmacology
IndicationMay be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
Structured Indications
PharmacodynamicsLosartan is the first of a class of antihypertensive agents called angiotensin II receptor blockers (ARBs). Losartan and its longer acting active metabolite, E-3174, are specific and selective type-1 angiotensin II receptor (AT1) antagonists which block the blood pressure increasing effects angiotensin II via the renin-angiotensin-aldosterone system (RAAS). RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: AT1 and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.
Mechanism of actionLosartan competitively inhibits the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. Losartan is metabolized to its active metabolite, E-3174, which is 10 to 40 times more potent than losartan and acts as a non-competitive AT1 antagonist. Inhibition of angiotensin II binding to AT1 inhibits its AT1-mediated vasoconstrictive and aldosterone-secreting effects and results in decreased vascular resistance and blood pressure. Losartan is 1,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion. Losartan is effective for reducing blood pressure and may be used to treat essential hypertension, left ventricular hypertrophy and diabetic nephropathy.
TargetKindPharmacological actionActionsOrganismUniProt ID
Type-1 angiotensin II receptorProteinyes
antagonist
HumanP30556 details
Related Articles
AbsorptionLosartan is well absorbed and undergoes substantial first-pass metabolism; the systemic bioavailability of losartan is approximately 33%. Mean peak concentrations of losartan and its active metabolite are reached in 1 hour and in 3-4 hours, respectively. While maximum plasma concentrations of losartan and its active metabolite are approximately equal, the AUC of the metabolite is about 4 times as great as that of losartan. When given with a meal, absorption is slows down and Cmax decreases.
Volume of distribution
  • 34 L [losartan, healthy subjects]
  • 12 L [active metabolite, healthy subjects]
Protein binding99.7% protein bound, primarily to albumin
Metabolism

Hepatic. Losartan is metabolized to a 5-carboxylic acid derivative (E-3174) via an aldehyde intermediate (E-3179) primarily by cytochrome P450 (CYP) 2C9 and CYP3A4. E-3174 is an active metabolite with 10- to 40-fold higher potency than its parent compound, losartan. Approxiamtely 14% of losartan is converted to E-3174; however, the AUC of E-3174 was found to be 4- to 8-fold higher than losartan and E-3174 is considered the main contributor to the pharmacologic effects of this medication.

SubstrateEnzymesProduct
Losartan
E-3179Details
Losartan
Losartan N2-glucuronideDetails
E-3179
E-3174Details
Route of eliminationFollowing oral administration of losartan, 35% of the dose is recovered in the urine and about 60% in the feces. Following an intravenous dose, 45% is recovered in the urine and 50% in the feces.
Half lifeThe terminal t1/2 of losartan is 2 hours. The active metabolite has a half-life of 6-9 hours.
Clearance
  • Total plasma clearance = 600 mL/min [losartan]
  • Total plasma clearance = 50 mL/min [active metabolite]
  • Renal clearance = 75 mL/min [losartan]
  • Renal clearance = 25 mL/min [active metabolite]
ToxicityHypotension and tachycardia; Bradycardia could occur from parasympathetic (vagal) stimulation, LD50= 1000 mg/kg (orally in rat)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Losartan Action PathwayDrug actionSMP00162
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Losartan can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe metabolism of Losartan can be decreased when combined with 2-mercaptobenzothiazole.Vet Approved
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Losartan.Experimental
AbirateroneThe serum concentration of Losartan can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Losartan is combined with Acebutolol.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Losartan.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Losartan.Approved
AcetaminophenThe serum concentration of Losartan can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Losartan is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Losartan is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Losartan.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Losartan is combined with Adapalene.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Losartan.Approved
AlbendazoleThe serum concentration of Losartan can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Losartan.Approved
AldosteroneThe serum concentration of Losartan can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Losartan can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Losartan can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Losartan.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Losartan.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Losartan.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Losartan.Approved, Investigational
AlosetronThe metabolism of Alosetron can be decreased when combined with Losartan.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Losartan.Approved, Illicit, Investigational
AlprenololLosartan may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmantadineThe serum concentration of Losartan can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Losartan.Approved, Investigational
AmifostineLosartan may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Losartan.Approved
Aminohippuric acidThe serum concentration of Losartan can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Losartan.Approved, Withdrawn
AmiodaroneThe metabolism of Losartan can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Losartan.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Losartan.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Losartan.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Losartan.Approved
AmorolfineThe metabolism of Losartan can be decreased when combined with Amorolfine.Approved
Amphotericin BThe metabolism of Losartan can be decreased when combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Losartan can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Losartan can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Losartan is combined with Amyl Nitrite.Approved
AN2690The metabolism of Losartan can be decreased when combined with AN2690.Investigational
AnidulafunginThe metabolism of Losartan can be decreased when combined with Anidulafungin.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Losartan is combined with Anisodamine.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Losartan.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Losartan.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Losartan is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Losartan is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Losartan is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Losartan can be increased when it is combined with Aprepitant.Approved, Investigational
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Losartan.Experimental
ArdeparinArdeparin may increase the hyperkalemic activities of Losartan.Approved, Withdrawn
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Losartan.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Losartan.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Losartan is combined with Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Losartan.Approved, Investigational
ArtemetherThe metabolism of Losartan can be decreased when combined with Artemether.Approved
AstemizoleThe serum concentration of Losartan can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Losartan can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Losartan.Approved
AtomoxetineThe metabolism of Losartan can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Losartan can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Losartan.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Azapropazone.Withdrawn
AzelastineThe serum concentration of Losartan can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Losartan is combined with Azilsartan medoxomil.Approved
AzithromycinThe serum concentration of Losartan can be increased when it is combined with Azithromycin.Approved
Bafilomycin A1The metabolism of Losartan can be decreased when combined with Bafilomycin A1.Experimental
BalsalazideThe risk or severity of adverse effects can be increased when Losartan is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Losartan.Experimental
BarbitalBarbital may increase the hypotensive activities of Losartan.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Losartan is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Losartan.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Losartan is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Losartan.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Losartan.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Benoxaprofen.Withdrawn
BenzocaineThe serum concentration of Losartan can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe metabolism of Losartan can be decreased when combined with Benzoic Acid.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Losartan.Approved
BepridilThe serum concentration of Losartan can be increased when it is combined with Bepridil.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be decreased when combined with Losartan.Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Losartan.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Losartan.Approved
BethanidineBethanidine may increase the hypotensive activities of Losartan.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Losartan is combined with Betulinic Acid.Investigational
BexaroteneThe serum concentration of Losartan can be decreased when it is combined with Bexarotene.Approved, Investigational
BifonazoleThe metabolism of Losartan can be decreased when combined with Bifonazole.Approved
BimatoprostLosartan may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Losartan can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Losartan.Approved
BoceprevirThe metabolism of Losartan can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Losartan can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Losartan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Losartan.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Losartan.Approved
BretyliumThe risk or severity of adverse effects can be increased when Losartan is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Losartan.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Losartan.Approved
BromfenacThe risk or severity of adverse effects can be increased when Losartan is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Losartan.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Losartan.Approved
BucillamineThe risk or severity of adverse effects can be increased when Losartan is combined with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Losartan is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Losartan is combined with Bupivacaine.Approved, Investigational
BupranololLosartan may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Losartan can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Losartan.Approved
BuspironeThe serum concentration of Losartan can be increased when it is combined with Buspirone.Approved, Investigational
ButenafineThe metabolism of Losartan can be decreased when combined with Butenafine.Approved
ButoconazoleThe metabolism of Losartan can be decreased when combined with Butoconazole.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Losartan.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Losartan.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Losartan.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Losartan.Experimental
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Losartan.Approved
CandesartanThe risk or severity of adverse effects can be increased when Losartan is combined with Candesartan.Approved
CandicidinThe metabolism of Losartan can be decreased when combined with Candicidin.Withdrawn
CandoxatrilThe risk or severity of adverse effects can be increased when Losartan is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Losartan can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Captopril.Approved
CarbamazepineThe metabolism of Losartan can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Losartan is combined with Carbetocin.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Losartan.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Losartan.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Losartan.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Losartan.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Losartan.Approved, Investigational
CaspofunginThe metabolism of Losartan can be decreased when combined with Caspofungin.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Losartan is combined with Castanospermine.Experimental
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Losartan.Approved, Investigational
CeliprololLosartan may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Losartan can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Losartan.Withdrawn
CertoparinCertoparin may increase the hyperkalemic activities of Losartan.Approved
CeruleninThe metabolism of Losartan can be decreased when combined with Cerulenin.Approved
ChloroquineThe serum concentration of Losartan can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Losartan is combined with Chlorothiazide.Approved, Vet Approved
ChloroxineThe metabolism of Losartan can be decreased when combined with Chloroxine.Approved
ChlorpromazineThe serum concentration of Losartan can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Losartan can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Losartan can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Losartan.Approved
CholecalciferolThe metabolism of Losartan can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Losartan can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Losartan can be decreased when it is combined with Cholic Acid.Approved
CiclopiroxThe metabolism of Losartan can be decreased when combined with Ciclopirox.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Losartan is combined with Cilnidipine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Losartan.Approved
CimetidineThe serum concentration of Losartan can be decreased when it is combined with Cimetidine.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Losartan.Approved
CiprofloxacinThe serum concentration of Losartan can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CiprofloxacinLosartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Losartan.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Losartan.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Losartan.Approved
ClarithromycinThe metabolism of Losartan can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Losartan can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Losartan is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Losartan.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Losartan is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Losartan can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Losartan.Approved, Investigational
ClomipramineThe serum concentration of Losartan can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Losartan.Approved
ClonixinThe risk or severity of adverse effects can be increased when Losartan is combined with Clonixin.Approved
ClopidogrelThe metabolism of Losartan can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Losartan can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Losartan.Approved
CobicistatThe metabolism of Losartan can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Losartan.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Losartan.Approved
ColforsinThe serum concentration of Losartan can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Losartan can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Losartan.Approved
CordycepinThe metabolism of Losartan can be decreased when combined with Cordycepin.Investigational
CrizotinibThe metabolism of Losartan can be decreased when combined with Crizotinib.Approved
CryptenamineLosartan may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Losartan is combined with Curcumin.Investigational
CyclophosphamideThe serum concentration of Losartan can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Losartan can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineLosartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Losartan.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Losartan is combined with D-Limonene.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Losartan.Approved
DabrafenibThe serum concentration of Losartan can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Losartan can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Losartan can be increased when it is combined with Dactinomycin.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Losartan.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Losartan is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Losartan.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Losartan.Approved, Investigational
DarunavirThe metabolism of Losartan can be decreased when combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Losartan.Approved
DasatinibThe serum concentration of Losartan can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Losartan can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Losartan.Approved
Decanoic AcidThe metabolism of Losartan can be decreased when combined with Decanoic Acid.Experimental
DeferasiroxThe serum concentration of Losartan can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Losartan can be decreased when combined with Delavirdine.Approved
DeserpidineLosartan may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Losartan is combined with Desflurane.Approved
DesipramineThe serum concentration of Losartan can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Losartan can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Losartan can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Losartan.Approved, Vet Approved
DextromethorphanThe serum concentration of Losartan can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Losartan.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Losartan.Approved
DiclofenacThe serum concentration of Losartan can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Losartan is combined with Diclofenamide.Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Losartan.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Losartan.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Losartan is combined with Diflunisal.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Losartan.Approved
DigoxinThe serum concentration of Losartan can be decreased when it is combined with Digoxin.Approved
DihydralazineLosartan may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe metabolism of Losartan can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Losartan.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Losartan.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Losartan is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Losartan.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Losartan is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Losartan.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Losartan.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Losartan.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Losartan.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Losartan.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Losartan.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Losartan.Approved
DoxepinThe serum concentration of Losartan can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Losartan.Approved, Investigational
DoxorubicinThe serum concentration of Losartan can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Losartan can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Losartan.Approved, Illicit
DronedaroneThe metabolism of Losartan can be decreased when combined with Dronedarone.Approved
DrospirenoneLosartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Losartan is combined with Droxicam.Approved
DuloxetineLosartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Losartan is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Losartan is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Losartan is combined with Ebselen.Investigational
EconazoleThe metabolism of Losartan can be decreased when combined with Econazole.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Losartan.Approved
EfavirenzThe serum concentration of Losartan can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe metabolism of Losartan can be decreased when combined with Efinaconazole.Approved
EfonidipineLosartan may increase the hypotensive activities of Efonidipine.Approved
ElbasvirThe serum concentration of Losartan can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Losartan.Approved, Investigational
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Losartan.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Losartan is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Losartan is combined with Enalaprilat.Approved
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Losartan.Approved
EnzalutamideThe serum concentration of Losartan can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Losartan.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Losartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Losartan.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Losartan.Approved
EprosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Eprosartan.Approved
ErgonovineThe serum concentration of Losartan can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Losartan can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Losartan.Approved, Investigational
ErythromycinThe metabolism of Losartan can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Losartan can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Losartan.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Losartan.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Losartan can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Losartan can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Losartan can be decreased when it is combined with Estrone.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Losartan.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Losartan is combined with Etanercept.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Losartan.Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Losartan.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Losartan is combined with Etofenamate.Approved
EtoposideThe serum concentration of Losartan can be increased when it is combined with Etoposide.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Losartan.Approved, Investigational
EtravirineThe serum concentration of Losartan can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Losartan is combined with Evening primrose oil.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Losartan.Approved
exisulindThe risk or severity of adverse effects can be increased when Losartan is combined with exisulind.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Losartan.Approved
FelodipineThe risk or severity of adverse effects can be increased when Losartan is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Losartan is combined with Fenbufen.Approved
FenoldopamLosartan may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Fenoprofen.Approved
FentanylThe serum concentration of Losartan can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Losartan.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Losartan.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Losartan.Approved
FimasartanThe risk or severity of adverse effects can be increased when Losartan is combined with Fimasartan.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Losartan is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe metabolism of Losartan can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Losartan can be decreased when it is combined with Fluconazole.Approved
FlucytosineThe metabolism of Losartan can be decreased when combined with Flucytosine.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Losartan.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Losartan.Approved, Illicit
FlunixinThe risk or severity of adverse effects can be increased when Losartan is combined with Flunixin.Vet Approved
FluorouracilThe metabolism of Losartan can be decreased when combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Losartan can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Losartan can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Losartan can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Losartan can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Losartan.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Losartan.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Losartan.Approved
FluvoxamineThe metabolism of Losartan can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Losartan.Approved, Investigational
FosamprenavirThe metabolism of Losartan can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Losartan can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Losartan can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Losartan.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Losartan is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Losartan can be increased when it is combined with Fusidic Acid.Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Losartan.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Losartan.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Losartan.Approved
GemfibrozilThe metabolism of Losartan can be decreased when combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Losartan can be increased when it is combined with Genistein.Investigational
GliclazideThe metabolism of Gliclazide can be decreased when combined with Losartan.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Losartan.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Losartan.Approved
GlyburideThe serum concentration of Losartan can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Losartan can be increased when it is combined with Glycerol.Experimental
GlyphosateThe metabolism of Losartan can be decreased when combined with Glyphosate.Experimental
Gramicidin DThe serum concentration of Losartan can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Losartan.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Losartan.Withdrawn
GriseofulvinThe metabolism of Losartan can be decreased when combined with Griseofulvin.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Losartan.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Losartan.Approved
GuanethidineLosartan may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Losartan is combined with Guanfacine.Approved, Investigational
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Losartan.Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Losartan.Approved
HaloproginThe metabolism of Losartan can be decreased when combined with Haloprogin.Approved, Withdrawn
HalothaneThe metabolism of Halothane can be decreased when combined with Losartan.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Losartan.Approved, Investigational
HexamethoniumLosartan may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe metabolism of Losartan can be decreased when combined with Hexetidine.Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Losartan.Approved
HigenamineThe risk or severity of adverse effects can be increased when Losartan is combined with Higenamine.Investigational
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Losartan.Approved
HMPL-004The risk or severity of adverse effects can be increased when Losartan is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Losartan.Approved
HydralazineThe risk or severity of adverse effects can be increased when Losartan is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Losartan is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Losartan.Approved, Vet Approved
HydroflumethiazideLosartan may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Losartan.Approved, Illicit
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Losartan.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Losartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Losartan is combined with Icatibant.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Losartan.Approved
IdelalisibThe serum concentration of Losartan can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Losartan.Approved
IloprostIloprost may increase the hypotensive activities of Losartan.Approved, Investigational
ImatinibThe metabolism of Losartan can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Losartan.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Losartan.Approved
IndapamideThe risk or severity of adverse effects can be increased when Losartan is combined with Indapamide.Approved
IndenololLosartan may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Losartan can be decreased when combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Losartan.Investigational
IndomethacinThe serum concentration of Losartan can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Indoprofen.Withdrawn
IndoraminLosartan may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Losartan.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Losartan.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Losartan is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Losartan.Approved, Investigational
IsavuconazoniumThe metabolism of Losartan can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Losartan.Approved
IsoconazoleThe metabolism of Losartan can be decreased when combined with Isoconazole.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Losartan is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Losartan is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Losartan is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Losartan is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Losartan is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Losartan.Approved
ItraconazoleThe metabolism of Losartan can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Losartan can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Losartan.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Losartan.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Losartan is combined with Kebuzone.Experimental
KetamineThe serum concentration of Losartan can be increased when it is combined with Ketamine.Approved, Vet Approved
KetanserinLosartan may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Losartan.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Losartan.Approved
KetoconazoleThe metabolism of Losartan can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Losartan.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Losartan is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Losartan.Approved
LacidipineLosartan may increase the hypotensive activities of Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Losartan.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Losartan.Approved, Investigational
LansoprazoleThe serum concentration of Losartan can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Losartan can be increased when it is combined with Lapatinib.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Losartan.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Losartan.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Losartan.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Losartan.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Losartan.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Losartan.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Losartan.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Losartan.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Losartan is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Losartan is combined with Levobupivacaine.Approved
LevodopaLosartan may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Losartan.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Losartan.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Losartan is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Losartan can be decreased when it is combined with Levothyroxine.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Losartan.Investigational
LidocaineThe serum concentration of Losartan can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Losartan.Approved
LiothyronineThe serum concentration of Losartan can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Losartan can be decreased when it is combined with Liotrix.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Losartan is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Losartan.Approved
LofexidineLosartan may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Losartan can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Losartan.Approved
LopinavirThe metabolism of Losartan can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Losartan can be increased when it is combined with Loratadine.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Losartan can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Losartan is combined with Loxoprofen.Approved
LuliconazoleThe serum concentration of Losartan can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Losartan can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Losartan.Approved, Investigational
MacitentanLosartan may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Losartan is combined with Magnesium salicylate.Approved
ManidipineLosartan may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Losartan is combined with Mannitol.Approved, Investigational
MaprotilineThe serum concentration of Losartan can be increased when it is combined with Maprotiline.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Losartan is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Losartan.Withdrawn
MebendazoleThe serum concentration of Losartan can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Losartan.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Losartan.Approved
MefloquineThe serum concentration of Losartan can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Losartan can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Losartan.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Losartan.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Losartan.Investigational, Withdrawn
MeprobamateThe serum concentration of Losartan can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineThe risk or severity of adverse effects can be increased when Losartan is combined with Mesalazine.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Losartan.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Losartan is combined with Metamizole.Withdrawn
MethadoneThe serum concentration of Losartan can be increased when it is combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Losartan is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Losartan.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Losartan.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Losartan.Approved, Vet Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Losartan.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Losartan is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Losartan.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Losartan.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Losartan.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Losartan.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Losartan is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Losartan.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Losartan.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Losartan.Approved
MetyrosineLosartan may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe metabolism of Losartan can be decreased when combined with Mevastatin.Experimental
MibefradilThe serum concentration of Losartan can be increased when it is combined with Mibefradil.Withdrawn
MicafunginThe metabolism of Losartan can be decreased when combined with Micafungin.Approved, Investigational
MiconazoleThe metabolism of Losartan can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Losartan can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Losartan can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe metabolism of Losartan can be decreased when combined with Miltefosine.Approved
MinaprineMinaprine may increase the hypotensive activities of Losartan.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Losartan.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Losartan.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Losartan.Approved
MitomycinThe serum concentration of Losartan can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Losartan can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Losartan can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Losartan is combined with Mizoribine.Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Losartan.Approved
ModafinilThe serum concentration of Losartan can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Losartan is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Losartan.Approved
MonensinThe metabolism of Losartan can be decreased when combined with Monensin.Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Losartan.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Losartan.Approved, Investigational
MoxonidineLosartan may increase the hypotensive activities of Moxonidine.Approved
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Losartan.Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Losartan.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Mycophenolic acid.Approved
MyxothiazolThe metabolism of Losartan can be decreased when combined with Myxothiazol.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Losartan is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Losartan is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Losartan is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Losartan.Approved
NafamostatThe risk or severity of adverse effects can be increased when Losartan is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Losartan can be decreased when it is combined with Nafcillin.Approved
NaftifineThe metabolism of Losartan can be decreased when combined with Naftifine.Approved
NaftopidilLosartan may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Losartan.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Losartan.Approved, Vet Approved
NaltrexoneThe serum concentration of Losartan can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Losartan.Approved, Vet Approved
NaringeninThe serum concentration of Losartan can be increased when it is combined with Naringenin.Experimental
NatamycinThe metabolism of Losartan can be decreased when combined with Natamycin.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Losartan.Approved, Investigational
NCX 4016The risk or severity of adverse effects can be increased when Losartan is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Losartan is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Losartan can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Losartan can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Losartan can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Losartan is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Losartan is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Losartan can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Losartan can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Losartan.Withdrawn
NicardipineThe metabolism of Losartan can be decreased when combined with Nicardipine.Approved
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Losartan.Approved, Vet Approved
NicorandilNicorandil may increase the hypotensive activities of Losartan.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Losartan.Approved
NifedipineThe risk or severity of adverse effects can be increased when Losartan is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Losartan is combined with Niflumic Acid.Approved
NiguldipineLosartan may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Losartan can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineLosartan may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Losartan is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Losartan.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Losartan.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Losartan.Approved
NitrazepamThe serum concentration of Losartan can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Losartan can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Losartan is combined with Nitric Oxide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Losartan is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Losartan is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Losartan.Approved
NitroxolineThe metabolism of Losartan can be decreased when combined with Nitroxoline.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Losartan.Approved
NorethisteroneThe serum concentration of Losartan can be decreased when it is combined with Norethisterone.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Losartan.Approved
NystatinThe metabolism of Losartan can be decreased when combined with Nystatin.Approved, Vet Approved
ObinutuzumabLosartan may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Losartan.Withdrawn
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Losartan.Approved, Investigational
OlaparibThe metabolism of Losartan can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Losartan.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Losartan.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Losartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Losartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Losartan is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Losartan.Approved
OmeprazoleThe serum concentration of Losartan can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Losartan.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Losartan is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Losartan can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Losartan.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Losartan.Approved
OxiconazoleThe metabolism of Losartan can be decreased when combined with Oxiconazole.Approved
OxprenololLosartan may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Losartan is combined with Oxyphenbutazone.Withdrawn
P-NitrophenolThe serum concentration of Losartan can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Losartan can be increased when it is combined with Paclitaxel.Approved, Vet Approved
pafuramidineThe metabolism of Losartan can be decreased when combined with pafuramidine.Investigational
PalbociclibThe serum concentration of Losartan can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Losartan can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Losartan.Approved, Investigational
PantoprazoleThe serum concentration of Losartan can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Losartan is combined with Papaverine.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Losartan.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Losartan.Approved
PargylinePargyline may increase the hypotensive activities of Losartan.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Losartan.Approved
ParoxetineThe serum concentration of Losartan can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Losartan.Approved
PenbutololThe risk or severity of adverse effects can be increased when Losartan is combined with Penbutolol.Approved, Investigational
PentamidineThe metabolism of Losartan can be decreased when combined with Pentamidine.Approved
PentobarbitalThe metabolism of Losartan can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumLosartan may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Losartan.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Losartan is combined with Perindopril.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Losartan.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Losartan.Withdrawn
PhenelzinePhenelzine may increase the hypotensive activities of Losartan.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Losartan.Withdrawn
PhenobarbitalThe metabolism of Losartan can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineLosartan may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Losartan.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Losartan.Approved
PhentolamineLosartan may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Losartan.Approved, Vet Approved
PhenytoinThe metabolism of Losartan can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Losartan is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Losartan can be increased when it is combined with Pimozide.Approved
PinacidilLosartan may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Losartan is combined with Pindolol.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Losartan.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Losartan is combined with Pipamperone.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Losartan is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Losartan.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Losartan.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Losartan.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Losartan.Withdrawn
Platelet Activating FactorThe serum concentration of Losartan can be decreased when it is combined with Platelet Activating Factor.Experimental
PolythiazideLosartan may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Losartan.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Losartan.Approved
PosaconazoleThe metabolism of Losartan can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Losartan is combined with Pramipexole.Approved, Investigational
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Losartan.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Losartan.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Losartan.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Losartan.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Losartan.Approved, Vet Approved
PrimidoneThe metabolism of Losartan can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Losartan can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Losartan can be decreased when it is combined with Progesterone.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Losartan.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Losartan.Approved, Vet Approved
PromethazineThe serum concentration of Losartan can be increased when it is combined with Promethazine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Losartan is combined with Propacetamol.Approved
PropafenoneThe serum concentration of Losartan can be increased when it is combined with Propafenone.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Losartan.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Losartan.Approved, Investigational
ProtriptylineThe serum concentration of Losartan can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Losartan.Approved
PTC299The risk or severity of adverse effects can be increased when Losartan is combined with PTC299.Investigational
PyrimethamineThe metabolism of Losartan can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Losartan.Approved, Illicit
QuercetinThe serum concentration of Losartan can be increased when it is combined with Quercetin.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Losartan is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Losartan can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Losartan can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Losartan.Approved
RabeprazoleThe metabolism of Losartan can be decreased when combined with Rabeprazole.Approved, Investigational
RadicicolThe metabolism of Losartan can be decreased when combined with Radicicol.Experimental
RamiprilThe risk or severity of adverse effects can be increased when Losartan is combined with Ramipril.Approved
RanitidineThe serum concentration of Losartan can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Losartan.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Losartan.Approved
ReboxetineThe serum concentration of Losartan can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Losartan can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Losartan is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Losartan.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Losartan.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Losartan is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Losartan.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Losartan is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Losartan.Approved
RifabutinThe metabolism of Losartan can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of Losartan can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Losartan can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Losartan.Approved, Investigational
RilmenidineLosartan may increase the hypotensive activities of Rilmenidine.Investigational
RilpivirineThe serum concentration of Losartan can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Losartan is combined with Riociguat.Approved
RisperidoneLosartan may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Losartan can be decreased when combined with Ritonavir.Approved, Investigational
RituximabLosartan may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Losartan.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Losartan.Investigational, Withdrawn
RolapitantThe serum concentration of Losartan can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Losartan.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Losartan is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Losartan is combined with Ropivacaine.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Losartan.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Losartan.Approved
RotigotineThe risk or severity of adverse effects can be increased when Losartan is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Losartan is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Losartan.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Losartan is combined with Salicylamide.Approved
Salicylhydroxamic AcidThe metabolism of Losartan can be decreased when combined with Salicylhydroxamic Acid.Experimental
Salicylic acidThe metabolism of Losartan can be decreased when combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Losartan is combined with Salsalate.Approved
SaprisartanLosartan may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Losartan can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Losartan can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Losartan can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Losartan can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Losartan.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Losartan.Approved, Investigational
SertaconazoleThe metabolism of Losartan can be decreased when combined with Sertaconazole.Approved
SertralineThe serum concentration of Losartan can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Losartan is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Losartan.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Losartan.Approved
SiltuximabThe serum concentration of Losartan can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Losartan can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Losartan can be increased when it is combined with Simvastatin.Approved
SinefunginThe metabolism of Losartan can be decreased when combined with Sinefungin.Experimental
SirolimusThe metabolism of Losartan can be decreased when combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Losartan.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Losartan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Losartan is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Losartan.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Losartan.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Losartan.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Losartan.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Losartan.Experimental
SpiraprilThe risk or severity of adverse effects can be increased when Losartan is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Losartan.Approved
SRT501The risk or severity of adverse effects can be increased when Losartan is combined with SRT501.Investigational
St. John's WortThe serum concentration of Losartan can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Losartan can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Losartan can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Losartan is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Losartan can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Losartan is combined with Sufentanil.Approved, Investigational
SulconazoleThe metabolism of Losartan can be decreased when combined with Sulconazole.Approved
SulfadiazineThe metabolism of Losartan can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Losartan.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Losartan.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Losartan is combined with Sulfasalazine.Approved
SulfinpyrazoneThe serum concentration of Losartan can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Losartan can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Losartan is combined with Sulindac.Approved
SumatriptanThe serum concentration of Losartan can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Losartan can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenThe metabolism of Suprofen can be decreased when combined with Losartan.Approved, Withdrawn
TacrineThe serum concentration of Losartan can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Losartan can be decreased when it is combined with Tacrolimus.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Losartan.Approved, Investigational
TamoxifenThe serum concentration of Losartan can be decreased when it is combined with Tamoxifen.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Losartan is combined with Tamsulosin.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Losartan.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Losartan.Experimental
TavaboroleThe metabolism of Losartan can be decreased when combined with Tavaborole.Approved
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Losartan.Approved, Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Losartan.Approved
TelaprevirThe metabolism of Losartan can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Losartan can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Losartan is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Losartan.Approved
TemocaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Losartan.Approved
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Losartan.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Losartan is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Losartan is combined with Terazosin.Approved
TerbinafineThe metabolism of Losartan can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe metabolism of Losartan can be decreased when combined with Terconazole.Approved
TerfenadineThe serum concentration of Losartan can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe metabolism of Losartan can be decreased when combined with Teriflunomide.Approved
TerlipressinLosartan may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe serum concentration of Losartan can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Losartan can be increased when it is combined with Testosterone.Approved, Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Losartan.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Losartan.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Losartan.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Losartan.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Losartan is combined with Thioridazine.Approved
ThymolThe metabolism of Losartan can be decreased when combined with Thymol.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Losartan is combined with Tiaprofenic acid.Approved
TiboloneLosartan may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Losartan.Approved
TiclopidineThe metabolism of Losartan can be decreased when combined with Ticlopidine.Approved
TicrynafenLosartan may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Losartan.Approved
TinoridineThe risk or severity of adverse effects can be increased when Losartan is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Losartan.Approved
TioconazoleThe metabolism of Losartan can be decreased when combined with Tioconazole.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Losartan.Approved
TocilizumabThe serum concentration of Losartan can be decreased when it is combined with Tocilizumab.Approved
TolazolineLosartan may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Losartan can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Losartan is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Losartan is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Losartan is combined with Tolmetin.Approved
TolnaftateThe metabolism of Losartan can be decreased when combined with Tolnaftate.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypotensive activities of Losartan.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Losartan.Approved, Investigational
TolvaptanTolvaptan may increase the hyperkalemic activities of Losartan.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Losartan.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Losartan.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Losartan.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Losartan.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Losartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Losartan is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Losartan.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Losartan.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Losartan.Approved
TravoprostTravoprost may increase the hypotensive activities of Losartan.Approved
TrazodoneThe serum concentration of Losartan can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Losartan.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Losartan.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Losartan.Approved
TrichlormethiazideLosartan may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Losartan can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Losartan can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinLosartan may increase the hypotensive activities of Trimazosin.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Losartan.Approved
TrimethaphanLosartan may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Losartan.Approved, Vet Approved
TrimetrexateThe metabolism of Losartan can be decreased when combined with Trimetrexate.Approved, Investigational
TrimipramineThe serum concentration of Losartan can be increased when it is combined with Trimipramine.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Losartan is combined with Trisalicylate-choline.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Losartan.Withdrawn
TroleandomycinThe serum concentration of Losartan can be increased when it is combined with Troleandomycin.Approved
UdenafilUdenafil may increase the antihypertensive activities of Losartan.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Losartan.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Losartan.Approved
UnoprostoneLosartan may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Losartan.Investigational, Withdrawn
Valproic AcidThe metabolism of Losartan can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Losartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Losartan.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Losartan.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Losartan.Approved
VenlafaxineThe metabolism of Losartan can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Losartan.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Losartan.Investigational
VinblastineThe serum concentration of Losartan can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Losartan.Approved, Investigational
VincristineThe serum concentration of Losartan can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Losartan can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineLosartan may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Losartan.Approved
VoriconazoleThe metabolism of Losartan can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Losartan.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Losartan.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Losartan.Approved, Investigational, Withdrawn
XylometazolineLosartan may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Losartan.Approved, Vet Approved
ZafirlukastThe metabolism of Losartan can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Losartan.Approved
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Losartan.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Losartan.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Losartan.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Losartan can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Losartan can be decreased when combined with Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Losartan.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Losartan is combined with Zomepirac.Withdrawn
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Losartan.Approved
Food Interactions
  • Take without regard to meals. Take at same time each day. Food delays absorption, but does not affect the extent of absorption.
References
Synthesis Reference

Gordon C. Campbell, Jr., Anil M. Dwivedi, Dorothy A. Levorse, James A. McCauley, Krishnaswamy S. Raghavan, “Polymorphs of losartan and the process for the preparation of form II of losartan.” U.S. Patent US5608075, issued May, 1994.

US5608075
General References
  1. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):995-1003. [PubMed:11937178 ]
  2. Guo ZX, Qiu MC: [Losartan downregulates the expression of transforming growth factor beta type I and type II receptors in kidney of diabetic rat]. Zhonghua Nei Ke Za Zhi. 2003 Jun;42(6):403-8. [PubMed:12895325 ]
  3. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC: Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006 Apr 7;312(5770):117-21. [PubMed:16601194 ]
  4. Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066 ]
  5. Stanfield, Cindy L.;Germann, William J. (2009). Principles of Human Physiology (3rd ed.). Benjamin-Cummings Publishing Company. [ISBN:978-0321556660 ]
  6. Bader, M. (2004). Renin-angiotensin-aldosterone system. In Encyclopedic reference of molecular pharmacology (pp. 810-814). Berlin: Springer. [ISBN:9783540298328 ]
External Links
ATC CodesC09DA01C09DB06C09CA01
AHFS Codes
  • 24:32.08
PDB EntriesNot Available
FDA labelDownload (212 KB)
MSDSDownload (19 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier-0.7812
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.6993
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IIInhibitor0.5309
Renal organic cation transporterNon-inhibitor0.5689
CYP450 2C9 substrateNon-substrate0.6839
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.6226
CYP450 1A2 substrateInhibitor0.5514
CYP450 2C9 inhibitorNon-inhibitor0.5423
CYP450 2D6 inhibitorNon-inhibitor0.8102
CYP450 2C19 inhibitorInhibitor0.6288
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7049
Ames testNon AMES toxic0.5382
CarcinogenicityNon-carcinogens0.6595
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6055 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5781
hERG inhibition (predictor II)Inhibitor0.8084
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Merck research laboratories div merck co inc
  • Teva pharmaceuticals usa inc
  • Merck & Co., Inc.
Packagers
Dosage forms
FormRouteStrength
TabletOral100.0 mg
TabletOral25.0 mg
TabletOral50.0 mg
TabletOral100 mg
TabletOral25 mg
TabletOral50 mg
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
Tablet, film coatedOral
TabletOral100 mg/1
TabletOral25 mg/1
TabletOral50 mg/1
TabletOral
Prices
Unit descriptionCostUnit
Losartan Potassium 90 50 mg tablet Bottle211.78USD bottle
Losartan Potassium-HCTZ 30 50-12.5 mg tablet Bottle78.05USD bottle
Hyzaar 100-25 mg tablet3.91USD tablet
Hyzaar 100-12.5 mg tablet3.87USD tablet
Hyzaar 100-12.5 tablet3.61USD tablet
Hyzaar 100-25 tablet3.61USD tablet
Losartan Potassium-HCTZ 100-12.5 mg tablet3.54USD tablet
Losartan Potassium-HCTZ 100-25 mg tablet3.54USD tablet
Cozaar 100 mg tablet3.41USD tablet
Losartan potassium 100 mg tablet3.14USD tablet
Hyzaar 50-12.5 mg tablet2.97USD tablet
Hyzaar 50-12.5 tablet2.65USD tablet
Cozaar 50 mg tablet2.5USD tablet
Losartan potassium 50 mg tablet2.26USD tablet
Cozaar 25 mg tablet1.92USD tablet
Losartan potassium 25 mg tablet1.72USD tablet
Cozaar 100 mg Tablet1.31USD tablet
Cozaar 25 mg Tablet1.31USD tablet
Cozaar 50 mg Tablet1.31USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1334092 No1995-01-242012-01-24Canada
CA2085584 No2003-02-112011-06-07Canada
US5210079 No1993-11-112010-11-11Us
US5608075 No1992-03-042009-03-04Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point184 °CPhysProp
water solubility0.82 mg/LNot Available
logP6.1Not Available
pKa5.5MERCK INDEX (1996); approx.
Predicted Properties
PropertyValueSource
Water Solubility0.0047 mg/mLALOGPS
logP4.5ALOGPS
logP5.08ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)7.4ChemAxon
pKa (Strongest Basic)4.12ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.51 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity131.85 m3·mol-1ChemAxon
Polarizability44.86 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as biphenyltetrazoles and derivatives. These are organic compounds containing a biphenyl attached to a tetrazole. A carbon atom of the biphenyl moiety is boned to a carbon or the nitrogen atom of the tetrazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassTetrazoles
Direct ParentBiphenyltetrazoles and derivatives
Alternative Parents
Substituents
  • Biphenyltetrazole
  • Biphenyl
  • 1,2,4,5-tetrasubstituted imidazole
  • Phenylmethylamine
  • Benzenoid
  • N-substituted imidazole
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Imidazole
  • Azacycle
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Sardo MA, Castaldo M, Cinquegrani M, Bonaiuto M, Fontana L, Campo S, Campo GM, Altavilla D, Saitta A: Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-alpha levels in uncomplicated hypertensive patients. Angiology. 2004 Mar-Apr;55(2):195-203. [PubMed:15026875 ]
  3. Dickstein K, Timmermans P, Segal R: Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure. Expert Opin Investig Drugs. 1998 Nov;7(11):1897-914. [PubMed:15991937 ]
  4. Anand-Srivastava MB, Palaparti A: Angiotensin-II-induced enhanced expression of Gi proteins is attenuated by losartan in A10 vascular smooth muscle cells: role of AT1 receptors. Can J Physiol Pharmacol. 2003 Feb;81(2):150-8. [PubMed:12710529 ]
  5. Rocha I, Bras-Rosario L, Amparo-Barros M, Silva-Carvalho L: Angiotensin AT1 receptor antagonist losartan and the defence reaction in the anaesthetised rat. Effect on the carotid chemoreflex. Exp Physiol. 2003 May;88(3):309-14. [PubMed:12719755 ]
  6. Guan J, Cheng DY, Chen XJ, Zhang Y, Wang H, Su QL: [The effects of losartan on pulmonary arterial collagen and AT1 in chronic hypoxic rats]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2004 Nov;35(6):774-7. [PubMed:15573751 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Song JC, White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy. 2000 Feb;20(2):130-9. [PubMed:10678291 ]
  2. Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F, Eliasson E, Dahl ML: Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther. 2002 Jan;71(1):89-98. [PubMed:11823761 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Song JC, White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy. 2000 Feb;20(2):130-9. [PubMed:10678291 ]
  2. Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814. [PubMed:16029066 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A3
Uniprot ID:
P35503
Molecular Weight:
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein kinase c binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A10
Uniprot ID:
Q9HAW8
Molecular Weight:
59809.075 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. The major substrates of this isozyme are eugenol > 4-methylumbelliferone > dihydrotestosterone (DHT) > androstane-3-alpha,17-beta-diol (3-alpha-diol) > testosterone > androsterone (ADT).
Gene Name:
UGT2B17
Uniprot ID:
O75795
Molecular Weight:
61094.915 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
  2. Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71. [PubMed:8621716 ]
  3. Soldner A, Benet LZ, Mutschler E, Christians U: Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol. 2000 Mar;129(6):1235-43. [PubMed:10725273 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Race JE, Grassl SM, Williams WJ, Holtzman EJ: Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun. 1999 Feb 16;255(2):508-14. [PubMed:10049739 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Urate transmembrane transporter activity
Specific Function:
Required for efficient urate re-absorption in the kidney. Regulates blood urate levels. Mediates saturable urate uptake by facilitating the exchange of urate against organic anions.
Gene Name:
SLC22A12
Uniprot ID:
Q96S37
Molecular Weight:
59629.57 Da
References
  1. Lipkowitz MS: Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep. 2012 Apr;14(2):179-88. doi: 10.1007/s11926-012-0240-z. [PubMed:22359229 ]
  2. Burnier M, Roch-Ramel F, Brunner HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 1996 Jun;49(6):1787-90. [PubMed:8743498 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sugar:proton symporter activity
Specific Function:
Transport urate and fructose. May have a role in the urate reabsorption by proximal tubules. Also transports glucose at low rate.
Gene Name:
SLC2A9
Uniprot ID:
Q9NRM0
Molecular Weight:
58701.205 Da
References
  1. Lipkowitz MS: Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep. 2012 Apr;14(2):179-88. doi: 10.1007/s11926-012-0240-z. [PubMed:22359229 ]
  2. Burnier M, Roch-Ramel F, Brunner HR: Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int. 1996 Jun;49(6):1787-90. [PubMed:8743498 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23